Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

NCT07130903 is registered in ClinicalTrials.gov with Barbara Ann Karmanos Cancer Institute as lead sponsor.

NCT NCT07130903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07130903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
September 10, 2025
Completion date
April 17, 2030
Enrollment
102 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal adenocarcinoma